NEW YORK (GenomeWeb News) – Protea Biosciences has licensed technology from Johns Hopkins University that it plans to use to develop tools for improving treatment of myocardial ischemia, the company said today.

The company has licensed technology developed in the lab of Hopkins researcher Jennifer Van Eyk that has been used to identify proteins bound to human serum albumin that are associated with cardiovascular disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.